Evaluation of improved quality of life with @entity4580 in the treatment of XXXX .

@entity1 @entity7646 @entity565 @entity117 @entity4580 @entity7187 @entity1412
INTRODUCTION: The Sino-Nasal Outcome Test 22 (SNOT-22) is an important tool in assessing the quality of life (QoL) of @entity1 with chronic rhinosinusitis with a validated version in Brazil. The @entity1412 ( @entity1412 ) represents most of the cases of @entity1412 (85-90%) and belongs to the group of chronic rhinosinusitis. It is a chronic inflammatory disease that impacts the QoL of @entity1 , not only causing localized symptoms, but also resulting in a general malaise. The standard treatments (corticosteroids and nasal endoscopic surgery) lead to partial control of symptoms, but relapses are frequent. @entity7646 acting as an immunomodulator is a promising tool for more effective control of this disease. Studies are still lacking to assess the real impact on the QoL in @entity1 treated with @entity7187 . OBJECTIVE: To evaluate the improvement of QL, evaluated using SNOT-22, in @entity1 with PNSE treated with immunomodulatory dose @entity4580 . METHODS: This is a paired experimental study in @entity1 with @entity1412 . Comparison of pre-treatment and post-treatment with @entity4580 was performed. @entity1 completed the SNOT-22 questionnaire before the start of treatment and returned for evaluation after eight weeks of treatment. @entity4580 was prescribed at a dose of 500mg, orally, three times a week, for 8 weeks. RESULTS: SNOT-22 score decreased 20.3 points on average. There was a significant decrease in the SNOT-22 (difference greater than 14 points) in 19 @entity1 (57.6%). There was no significant difference in improvement in SNOT in subgroups with or without @entity565 / @entity117 intolerance. CONCLUSION: @entity4580 resulted in significant improvement of QoL, assessed by SNOT-22, in the studied population.
